These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1889626)

  • 1. Chirality and its importance in drug development: what are the issues?
    Beckett AH
    Biochem Soc Trans; 1991 Apr; 19(2):443-6. PubMed ID: 1889626
    [No Abstract]   [Full Text] [Related]  

  • 2. Chirality and its importance in drug development: a synthetic chemist's perspective.
    Roberts SM
    Biochem Soc Trans; 1991 Apr; 19(2):446-53. PubMed ID: 1889627
    [No Abstract]   [Full Text] [Related]  

  • 3. Chirality and its importance in drug development: an analytical chemist's perspective.
    Fell AF; Ley GW
    Biochem Soc Trans; 1991 Apr; 19(2):454-6. PubMed ID: 1889628
    [No Abstract]   [Full Text] [Related]  

  • 4. Overview of the perspectives devoted to tautomerism in molecular design.
    Martin YC
    J Comput Aided Mol Des; 2010 Jun; 24(6-7):473-4. PubMed ID: 20428926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chirality and its importance in drug development.
    Campbell DB; Wilson K
    Biochem Soc Trans; 1991 Apr; 19(2):472-5. PubMed ID: 1889635
    [No Abstract]   [Full Text] [Related]  

  • 6. Chirality in new drug development. Clinical pharmacokinetic considerations.
    Nation RL
    Clin Pharmacokinet; 1994 Oct; 27(4):249-55. PubMed ID: 7834962
    [No Abstract]   [Full Text] [Related]  

  • 7. Practical synthesis of pharmaceutically relevant molecules enriched in sp
    Campbell PS; Jamieson C; Simpson I; Watson AJB
    Chem Commun (Camb); 2017 Dec; 54(1):46-49. PubMed ID: 29189836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chirality and drugs in clinical practice and its ethical aspect.
    Banerjee M; Biswas I; Halder S
    J Indian Med Assoc; 2009 Jan; 107(1):41-2. PubMed ID: 19588688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The art of building small: from molecular switches to molecular motors.
    Feringa BL
    J Org Chem; 2007 Aug; 72(18):6635-52. PubMed ID: 17629332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyamorphism: a pharmaceutical science perspective.
    Hancock BC; Shalaev EY; Shamblin SL
    J Pharm Pharmacol; 2002 Aug; 54(8):1151-2. PubMed ID: 12195833
    [No Abstract]   [Full Text] [Related]  

  • 11. Proteomics profile of cellular response to chiral drugs: prospects for pharmaceutical applications.
    Bun Ching C; Zhang J; Sui J; Ning Chen W
    Proteomics; 2010 Feb; 10(4):888-93. PubMed ID: 19953539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active isomer medications: new and improved or just repackaged?
    Johnson TJ
    S D J Med; 2001 Sep; 54(9):359-60. PubMed ID: 11577623
    [No Abstract]   [Full Text] [Related]  

  • 13. The importance of characterizing the crystal form of the drug substance during drug development.
    Clas SD
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):550-60. PubMed ID: 12951818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Chirality in Drugs: An Overview.
    Alkadi H; Jbeily R
    Infect Disord Drug Targets; 2018; 18(2):88-95. PubMed ID: 28356054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of biopharmaceuticals: current issues.
    Strohl WR; Knight DM
    Curr Opin Biotechnol; 2009 Dec; 20(6):668-72. PubMed ID: 19896824
    [No Abstract]   [Full Text] [Related]  

  • 16. Biocatalysis: synthesis of chiral intermediates for drugs.
    Patel RN
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):741-64. PubMed ID: 17117684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of atropisomerism in drug discovery.
    Clayden J; Moran WJ; Edwards PJ; LaPlante SR
    Angew Chem Int Ed Engl; 2009; 48(35):6398-401. PubMed ID: 19637174
    [No Abstract]   [Full Text] [Related]  

  • 18. Pediatric Drug Development and Dosage Form Design.
    Preis M; Breitkreutz J
    AAPS PharmSciTech; 2017 Feb; 18(2):239-240. PubMed ID: 28116597
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current status and promising future of pharmaceutical cocrystals in development of oral dosage forms].
    Fukami T
    Nihon Yakurigaku Zasshi; 2017; 150(1):36-40. PubMed ID: 28690273
    [No Abstract]   [Full Text] [Related]  

  • 20. A primer of deuterium in drug design.
    Cargnin S; Serafini M; Pirali T
    Future Med Chem; 2019 Aug; 11(16):2039-2042. PubMed ID: 31538524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.